• CapsoVision expects to submit CapsoCam Colon Gen 2 for FDA clearance in Q4 2026, targeting an initial $1 billion U.S. market.
• CapsoCam Plus generated $3.6 million in third-quarter 2026 revenue.
• The small-bowel AI module launched in the U.S. on November 2, 2026, following FDA clearance on September 25, 2026.
• An $18 million registered direct offering was completed in September 2026; a $100 million ATM facility was established in August 2026.
• No debt was outstanding as of September 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capso Vision Inc. published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.